By CEDAR BURNETT, Associated Press

In this age of heightened anxiety, many of us turn to our pets for emotional support. But is our behavior increasing our furry friends’ fears?

The answer isn’t simple, says Frankie Jackson, a veterinary nurse and animal behavior consultant, and the owner of Canine Counseling in Smyrna, Georgia. She said she’s seen an increase in anxiety among her animal and human clients, but that it’s hard to unwind the cause and effect.

“Dogs are incredibly responsive to our expressions, our body language and our scent,” she says. “There is a feedback loop — the owners are nervous; the dog gets nervous. Our cortisol levels rise and fall in tandem.”

Dr. Becky Peters, a veterinarian and owner of Bath Veterinary Hospital in Bath, New York, has also noticed a link between the anxiety of pets and their owners, particularly in the exam room.

“If owners try to over comfort them — lots of ‘you’re OK!’” in anxious voices, the animals do get more anxious. If we stay calm and quiet, they do too,” Peters says.

This undated photo released by Dr. Becky Peters, a veterinarian and owner of Bath Veterinary Hospital in Bath, N.Y., shows Peters with her dog. (AP Photo/Becky Peters)

Peters attributes much of the rise in pet anxiety to the social upheaval of the COVID years. Many animals who were acquired during the pandemic had limited opportunities to socialize with other people and pets during their peak developmental stages. After COVID, pets who were used to having their family at home experienced separation anxiety as their owners returned to work and school.

“A lot of pet anxiety comes from changes to their households,” Peters says. “It can also occur from a lack of routine and structure and not enough physical activity.”

Other components that could contribute to our pets’ anxiety include unmet needs, past trauma and insufficient open spaces.

“We are asking our dogs to live in a world that isn’t made for them,” she says.

Try to get at the cause of your pet’s anxiety

Low-level stress responses in dogs, such as eating less and excessive self-grooming, are forms of communication that precede lunging and barking, Jackson says. Trying to solve reactive behaviors through obedience training without addressing the root cause can make dogs’ anxiety worse.

“It’s important to understand what the dogs are saying and why they’re behaving the way they are. Manners and life skills are important, but it won’t create happy dogs,” Jackson says.

Anxiety in cats can be harder to spot, according to Jackson, because they’re hard-wired to hide it. While dogs seek out their support people, cats don’t feel safe expressing their vulnerability. Urinating in the house, scratching, hiding under the bed and overgrooming can be signs that your kitty is anxious.

First, see a vet

If your animal companion is suddenly acting out or on a licking binge, Jackson advises seeing a veterinarian to rule out a medical cause, such as pain or allergies.

Veterinarians can also prescribe anti-anxiety medication and complementary treatments to promote sleep and relaxation. Peters recommends supplements for her canine clients including probiotics and the amino acids l-theanine and tryptophan (yes, the turkey coma one).

For cats, she suggests using a product like Feliway that diffuses calming pheromones into the air.

Learn about the breed

A dog’s breed might also play a part in developing anxiety. Peters says that while every dog is different, the more active herding and working breeds like shepherds and border collies can become anxious and destructive without an outlet for their energy.

“Herding breeds need space to run and jobs to do,” she says.

When Tacoma, Washington, resident Shelani Vanniasinkam got her Australian shepherd puppy, Roo, she didn’t know about the breed’s reputation for anxiety. Her previous dog had been an easygoing husky who enjoyed pats from strangers and visits to the dog park. She quickly realized Roo was not that type of dog.

“He had a lot more needs than we anticipated,” Vanniasinkam says. “We couldn’t leave him alone for more than 30 minutes.”

This undated photo released by Shelani Vanniasinkam shows her dog Roo appears by an obstacle course at one of his favorite Sniffspots in Puyallup, Wash. Sniffspots are locations that pet owners can rent by the hour for solo off-leash dog play. (AP Photo/Shelani Vanniasinkam)

Vanniasinkam and her husband, Jesus Celaya, reached out to a local pet behavioralist, but it became clear that Roo’s anxiety was so acute he needed medication before he could start behavior training.

Should you consider meds for an anxious pet?

Medication can be important in behavioral treatment, but it shouldn’t be the only approach, says Peters. She usually suggests that her clients try training and routine modification first, unless their pet is causing harm to themselves or others.

“If I’m going to use meds, it’s part of a greater process,” Peters says.

Related Articles

A revolutionary drug for extreme hunger offers clues to obesity’s complexity

Guns kill more US children than other causes, but state policies can help, study finds

‘Expensive and complicated’: Most rural hospitals no longer deliver babies

How to stay cool in the heat wave hitting parts of the US — even without air conditioning

More employers adopting ICHRAs, giving workers money to buy their own health insurance

Roo’s veterinarian put him on Fluoxetine, or “doggie Prozac,” an antidepressant commonly given to anxious pets. He also prescribed Trazodone, another antidepressant, for particularly stressful events, such as trips to the vet or a night of fireworks.

After starting his medication, Roo received eight months of behavior training, during which Vanniasinkam and her husband not only changed their own approach to dog parenting but also set boundaries with friends and family. They limited Roo’s interaction with other dogs, asked people to stop using their doorbell and requested that others ignore Roo when he barks.

Now, when they want to take Roo for off-leash play, they book time at a local Sniffspot, which Vanniasinkam describes as “an Airbnb for anxious and reactive dogs.” The company, which launched in 2016, allows homeowners to rent out their yards or property by the hour for solo, off-leash play or doggie playdates.

“It’s sad when you can’t take your dog to a dog park,” Vanniasinkam says. “So, this option is really nice.”

She says that while it was initially difficult to navigate Roo’s anxiety, he is loving, family-oriented and worth the effort.

“It’s hard having an anxious dog, but you can figure it out,” she says. “It’s just important to understand your dog, so you’re set up for success.”

By Claire Sibonney, KFF Health News

Ali Foley Shenk still remembers the panic when her 10-year-old son, Dean, finished a 20-ounce box of raisins in the seconds the cupboard was left unlocked. They rushed to the emergency room, fearing a dangerous bowel impaction.

The irony stung: When Dean was born, he was so weak and floppy he survived only with feeding tubes because he couldn’t suck or swallow. He was diagnosed as a baby with Prader-Willi syndrome — a rare disorder sparked by a genetic abnormality. He continued to be disinterested in food for years. But doctors warned that as Dean grew, his hunger would eventually become so uncontrollable he could gain dangerous amounts of weight and even eat until his stomach ruptured.

“It’s crazy,” said Foley Shenk, who lives in Richmond, Virginia. “All of a sudden, they flip.”

Prader-Willi syndrome affects up to 20,000 people in the U.S. The most striking symptom is its most life-threatening: an insatiable hunger known as hyperphagia that prompts caregivers to padlock cupboards and fridges, chain garbage cans and install cameras. Until recently, the only treatment was growth hormone therapy to help patients stay leaner and grow taller, but it didn’t address appetite.

In March, the Food and Drug Administration approved Vykat XR, an extended-release version of the existing drug diazoxide choline, which eases the relentless hunger and may offer insights into the biology of extreme appetite and binge eating. This breakthrough for these patients comes as other drugs are revolutionizing how doctors treat obesity, which affects more than 40% of American adults. GLP-1 agonist medications Ozempic, Wegovy and others also are delivering dramatic results for millions.

But what’s becoming clear is that obesity isn’t one disease — it’s many, said Jack Yanovski, a senior obesity researcher at the National Institutes of Health, who co-authored some of the Vykat XR studies. Researchers are learning that obesity’s drivers can be environmental, familial or genetic. “It only makes sense that it’s complex to treat,” Yanovski said.

Obesity medicine is likely heading the way of treatments for high blood pressure or diabetes, with three to five effective options for different types of patients. For example, up to 15% of patients in the GLP-1 trials didn’t respond to those drugs, and at least one study found the medications didn’t significantly help Prader-Willi patients.

Yet, researchers say, efforts to understand how to treat obesity’s many causes and pathways are now in question as the Trump administration is dismantling the nation’s infrastructure for medical discovery.

While Health and Human Services Secretary Robert F. Kennedy Jr. promotes a “Make America Healthy Again” agenda centered on diet and lifestyle, federal funding for health research is being slashed, including some grants that support the study of obesity. University labs face cuts, FDA staffers are being laid off en masse, and rare disease researchers fear the ripple effects across all medical advances. Even with biotech partnerships — such as the work that led to Vykat XR — progress depends on NIH-funded labs and university researchers.

“That whole thing is likely to get disrupted now,” said Theresa Strong, research director for the Foundation for Prader-Willi Research.

HHS spokesperson Andrew Nixon said in a statement that no NIH awards for Prader-Willi syndrome research have been cut. “We remain committed to supporting critical research into rare diseases and genetic conditions,” he said.

But Strong said that already some of the contacts at the FDA she’d spent nearly 15 years educating about the disorder have left the agency. She’s heard that some research groups are considering moving their labs to Europe.

Ali Foley Shenk, left, and her son Dean, at their home in Richmond, Virginia. (Parker Michels-Boyce/KFF Health News/TNS)

Early progress in hunger and obesity research is transforming the life of Dean Shenk. During the trial for Vykat XR, his anxiety about food eased so much that his parents began leaving cupboards unlocked.

Jennifer Miller, a pediatric endocrinologist at the University of Florida who co-led the Vykat XR trials, treats around 600 Prader-Willi patients, including Dean. She said the impact she’s seen is life-changing. Since the drug trial started in 2018, some of her adult patients have begun living independently, getting into college, and starting jobs — milestones that once felt impossible. “It opens up their world in so many ways.”

Over 26 years in practice, she’s also seen just how severely the disease hurts patients. One patient ate a four-pound bag of dehydrated potato flakes; another ingested all 10 frozen pizzas from a Costco pack; some ate pet food. Others have climbed out of windows, dived into dumpsters, even died after being hit by a car while running away from home in search of food.

Low muscle tone, developmental delays, cognitive disabilities and behavioral challenges are also common features of the disorder.

Dean attends a special education program, his mother said. He also has narcolepsy and cataplexy — a sudden loss of muscle control triggered by strong emotions. His once-regular meltdowns and skin-picking, which led to deep, infected lesions, were tied to anxiety over his obsessive, almost painful urge to eat.

In the trial, though, his hyperphagia was under control, according to Miller and Dean’s mother. His lean muscle mass quadrupled, his body fat went down, and his bone mineral density increased. Even the skin-picking stopped, Foley Shenk said.

Vykat XR is not a cure for the disease. Instead, it calms overactive neurons in the hypothalamus that release neuropeptide Y — one of the body’s strongest hunger signals. “In most people, if you stop secreting NPY, hunger goes away,” said Anish Bhatnagar, CEO of Soleno Therapeutics, which makes the medication, the company’s first drug. “In Prader-Willi, that off switch doesn’t exist. It’s literally your brain telling you, ‘You’re starving,’ as you eat.”

GLP-1 drugs, by contrast, mimic a gut hormone that helps people feel full by slowing digestion and signaling satiety to the brain.

Vykat XR’s possible side effects include high blood sugar, increased hair growth and fluid retention or swelling, but those are trade-offs that many patients are willing to make to get some relief from the most devastating symptom of the condition.

Related Articles

In stressful times, our anxiety can rub off on pets. Causes and cures for pet anxiety

Guns kill more US children than other causes, but state policies can help, study finds

‘Expensive and complicated’: Most rural hospitals no longer deliver babies

How to stay cool in the heat wave hitting parts of the US — even without air conditioning

More employers adopting ICHRAs, giving workers money to buy their own health insurance

Still, the drug’s average price of $466,200 a year is staggering even for rare-disease treatments. Soleno said in a statement it expects broad coverage from both private and public insurers and that the co-payments will be “minimal.” Until more insurers start reimbursing the cost, the company is providing the drug free of charge to trial participants.

Soleno’s stock soared 40% after the FDA nod and has held fairly steady since, with the company valued at nearly $4 billion as of early June.

While Vykat XR may be limited in whom it can help with appetite control, obesity researchers are hoping the research behind it may help them decode the complexity of hunger and identify other treatment options.

“Understanding how more targeted therapies work in rare genetic obesity helps us better understand the brain pathways behind appetite,” said Jesse Richards, an internal medicine physician and the director of obesity medicine at the University of Oklahoma-Tulsa’s School of Community Medicine.

That future may already be taking shape. For Prader-Willi, two other notable phase 3 clinical trials are underway, led by Acadia Pharmaceuticals and Aardvark Therapeutics, each targeting different pathways. Meanwhile, hundreds of trials for general obesity are currently recruiting despite the uncertainties in U.S. medical research funding.

That brings more hope to patients like Dean. Nearly six years after starting treatment, the now-16-year-old is a calmer, happier kid, his mom said. He’s more social, has friends, and can focus better in school. With the impulse to overeat no longer dominating his every thought, he has space for other interests — “Star Wars,” “American Ninja Warrior” and a healthy appreciation for avocados among them.

“Before the drug, it just felt like a dead end. My child was miserable,” Foley Shenk said. “Now, we have our son back.”

©2025 KFF Health News. Distributed by Tribune Content Agency, LLC.

One of the faintest Zodiac constellations in the night sky is the constellation Libra, the Scales. Like most constellations, good luck seeing it for what it’s supposed to be. It allegedly outlines scales, the universal symbol of justice. Libra only has two stars you can realistically see with the naked eye, and the names of those stars are the toughest tongue twisters you’ll ever come across. They are Zubeneschamali, pronounced zuba-nes-sha-molly, and Zubenelgenubi, pronounced zoo-been-nel-jay-new-bee. Just try to say these names 10 times as fast as you can. I hope you don’t bite your tongue! I just call them the Z stars.

(Mike Lynch)

Libra and the Z stars are visible in the very low southern sky after evening twilight. You really need a good view of the southern horizon, one that doesn’t have much of a tree line. The best way to locate Libra and the Z stars is to use the three stars that outline the head of the adjacent constellation Scorpius, just starting to rise above the southeast horizon. Look for three moderately bright stars evenly spaced in a short diagonal line. They should be easy to see. Just to the right of those stars is Libra with Zubeneschamali and Zubenelgenubi. The Z stars will be oriented diagonally, with Zubeneschamali on the upper left and Zubenelgenubi on the lower right. For sure, they’ll be the brightest stars in that immediate area.

These tongue-twisting Z stars are Arabic names that roughly translate to English as the northern claw and southern claw, respectively. What do “claw” stars have to do with the scales of justice? Absolutely nothing! As it turns out, the constellation Libra was invented by the Roman Empire’s Julius Caesar around the time of Christ. Originally, the Z stars of Libra were seen as the claws of the neighboring constellation Scorpius the Scorpion. Since he was an all-powerful emperor, Caesar decreed that the claws of Scorpius be hacked off and made the Z stars and a few others around them into the new constellation Libra the Scales. Nobody dared to disagree!

As with many stars, Zubenelgenubi appears to the naked eye as a single star, but like many stars, it’s actually a binary system made up of two stars, revolving around each other, 77 light-years away from Earth. If you’re new to this column, light years are the easiest way to describe the incredible distance to the stars. A light year is defined as the distance a beam of light travels in a year, about 5.8 trillion miles. Zubenelgenubi is nearly 440 trillion miles away.

Zubeneschamali is even farther away, 185 light-years distant. It’s a blue giant star well over 4 million miles in diameter. Our own sun isn’t even a million miles across. Its surface temperature is believed to be over 22,000 degrees Fahrenheit, more than twice as hot as our sun.

Before you catch your nightly Z’s, try to catch the Z stars of Libra in the low southern sky just after evening twilight. Don’t feel bad if you can’t pronounce them though. I’ve been stargazing for over half a century and still disastrously stumble on them.

Mike Lynch is an amateur astronomer and retired broadcast meteorologist for WCCO Radio in Minneapolis/St. Paul. He is the author of “Stars: a Month by Month Tour of the Constellations,” published by Adventure Publications and available at bookstores and adventurepublications.net. Mike is available for private star parties. You can contact him at mikewlynch@comcast.net.

Related Articles

Skywatch: A telescope revolution is here

Skywatch: Constant Capella

Skywatch: June stargazing — the great late show

Skywatch: High heavenly hair

Skywatch: Virgo the Virgin, a large but faint constellation

LINDSAY DAVIS: Award-winning British author introduces “There Will Be Bodies,” the latest in her Flavia Albia series set in first-century Rome, where Flavia has to solve the mystery of bodies found in a villa being restored. 6:30 p.m. Tuesday, Once Upon a Crime, 604 W. 26th St., Mpls.

STEVE GROVE: CEO/publisher of Star Tribune launches “How I Found Myself in the Midwest: A Memoir of Reinvention,” in which he tells of leaving Silicon Valley in California to return to Minnesota where he took a position in state government with Gov. Tim Walz. After surviving the crises of pandemic restrictions, navigating deep divisions in the state and working to redevelop neighborhoods, he writes of how to give meaning to life and why he is optimistic about the United States’ future. Presented on Tuesday by Magers & Quinn. The Parkway Theater, 4814 Chicago Ave., Mpls.  6 p.m. music by AirLands, 7 p.m. Q and A moderated by Alison Kaplan, president of content for MSP Communications’ Cities Media Group. $15-20. Tickets at Facebook RSVP.

MIDWEST BOOKISH FEST: More than two dozen authors of books in all genres and 20 vendors will be showcased at this book festival for readers of all ages, including panels, a masquerade and a fairy tea party. Friday-Saturday, Minneapolis Marriott West, 9960 Wayzata Blvd., Mpls. $213. Information: midwestbookishfest.com

Related Articles

Literary calendar for week of June 15

Literary calendar for week of June 8

Two artists awarded $25K as McKnight Book Artist Fellows

Literary calendar for week of June 1

Literary calendar for week of May 18: ‘Weird, Sad and Silent’